Project: Angiogenesis in human and animal hepatocellular carcinoma (HCC). A translational approach.
01/10/10 – 30/09/15
Primary liver cancer or hepatocellular carcinoma ranks as the fifth most common cancer worldwide Blood vessel formation to provide oxygen is of extreme importance for the tumour to grow. Several factors inducing blood vessel formation are spread by the tumour (VEGF,PIGD). Sorafenib (anti-VEGF) is a licensed drug for HCC which inhibits blood vessel formation. However it is suggested that under this treatment the tumour could find escape pathways to form new blood vessels to rpovide the tumour with oxygen. The cenral theme and hypothesis of the research project is that angiogenic pathways other than VEGF are present in HCC and can be udes as a therapeutic target. Our research will foucs on two possible pathways involved in angiogenesis: PIGF (in mice and human) and PHD2 (in mice).